Takeda Forms Partnerships for IBD
Takeda Pharmaceuticals U.S.A., Inc. has formed a multi-year research partnership with two academic centers with a focus on inflammatory bowel disease (IBD) research and care. The partnership, with the University of Chicago and the Icahn School of Medicine at Mount Sinai in New York, will help to further patient care through the increased study of IBD. Takeda is developing treatments and patient-centered support, with initiatives directed at digital innovation and IBD and immunology and IBD.
During the three-year partnership, the University of Chicago will work to establish a unique patient physician digital platform that communicates real-time disease status, collates environmental, molecular, genetic and microbiome factors for each patient and creates a system for identifying personalized IBD therapy. Mount Sinai will focus on immunology in IBD, including discovering novel paradigms of lymphocytic homing to the colon, identifying the effect of the microbiome on homing to the colon, and exploring therapeutic cell-based approaches to suppress intestinal inflammation. The collaboration was facilitated through Mount Sinai Innovation Partners, an internal business unit of the Mount Sinai Health System that facilitates the real-world application and commercialization of Mount Sinai discoveries and the development of research partnerships.
Takeda recently acquired a US-based biologics manufacturing facility that will focus on producing a treatment for ulcerative colitis (UC) and Crohn's disease (CD), the two most common forms of IBD. The acquisition of the facility will allow Takeda to further support US patients with UC and CD.
Source: Takeda Pharmaceutical